Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis
Knee Osteoarthritis
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Knee, osteoarthritis, plasma rich in growth factors, platelet rich plasma, hyaluronic acid
Eligibility Criteria
Inclusion Criteria:
- Age above 55.
- Moderate to severe symptoms according to the WOMAC pain score of more than 6 months of evolution.
- Grade II - III knee osteoarthritis radiographic criteria for the classification of Kellgren and Lawrence.
- BMI Index below 35 which is considered Morbid Obesity according to WHO.
- Absence of treatments for osteoarthritis in the last 6 months.
Exclusion Criteria:
- Patients who have previously received medical treatment through viscosupplementation in the last 6 months.
- Patients who have allergies to some of the components of DUROLANE ® either hyaluronic acid itself or any of its excipients.
- Patients with severe angular changes and joint instability.
- Patients on anticoagulants or antiplatelet treatment that may not temporarily reversed for infiltrations.
- Polyarticular disease
- Infectious Diseases
- Tumor processes on treatment or medical care.
- Immunosuppressive therapy or immunosuppressive processes.
- Inability to understand the health questionnaires and / or adequately complete.
Sites / Locations
- Hospital Universitario Principe de Asturias
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Plasma rich in growth factors (PRGF)
Hyaluronic acid (Durolane®)
Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days. Procedure for the application of the treatment: 1. Study Group or PRGF group Blood sample : Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose. 20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis. Spinning of the sample: 8 minutes at 1800 rpm . getting the blood fraction containing the PRGF activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma. the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination.
Patients in this group will receive a single intra-articular injection at visit 1.